|
Year
|
Sites
|
Day 3 + (%)
|
ACPR (%)
|
LCF (%)
|
LPF (%)
|
ETF (%)
|
WTH/LFU (%)
|
|---|
|
2010c
|
Yingjiang
|
5.9% (1/29)
|
100.0% (20/20)
|
0.0% (0/20)
|
0.0% (0/20)
|
0.0% (0/20)
|
31.0% (9/29)
|
|
2012c
|
Yingjiang
|
3.9% (2/50)
|
100.0% (43/43)a
|
0.0% (0/43)
|
0.0% (0/43)
|
0.0% (0/43)
|
14.0% (7/50)
|
|
2012c
|
Tengchong
|
4.5% (1/22)
|
100.0% (20/20)
|
0.0% (0/20)
|
0.0% (0/20)
|
0.0% (0/20)
|
9.1% (2/22)
|
|
2013
|
Yingjiang
|
9.5% (2/22)
|
100.0% (20/20)
|
0.0% (0/20)
|
0.0% (0/20)
|
0.0% (0/20)
|
9.1% (2/22)
|
|
2013
|
Ruili
|
0.0% (0/11)
|
100.0% (6/6)
|
0.0% (0/6)
|
0.0% (0/6)
|
0.0% (0/6)
|
45.5% (5/11)
|
|
2014
|
Menglian
|
2.5% (1/40)
|
96.8% (30/31)
|
3.1% (1/31)b
|
0.0% (0/31)
|
0.0% (0/31)
|
22.5% (9/40)
|
- ACPR, adequate clinical parasitological response; LCF, late clinical failure; LPF, late parasitological failure; ETF, early treatment failure; WTH, withdrawal; LFU, loss to follow-up
- aOne of 43 participants had parasite and fever on day 3, but this case was continually followed up and cleared parasitaemia without rescue treatment and was finally classified to be ACPR
- bP. vivax infection was positive on day 35
- cPart data of the therapeutic efficacy study of DHA-PPQ has been presented in another study [7]
